Active case

Toxic Exposure /

Hair Relaxer Lawsuit

Hair Relaxer Lawsuit

Recent research has found a link between the chemicals in hair relaxer products and ovarian, uterine and endometrial cancer.

Connect with an attorney

Case Overview

Hair relaxer lawsuits allege companies like L’Oréal and Revlon manufactured dangerous products that led to people developing cancer. Studies have linked hair relaxer chemicals to multiple types of cancer. People who developed these cancers after using hair relaxers may be able to file a hair relaxer lawsuit.

Key hair relaxer lawsuit takeaways

  • Multiple hair relaxer lawsuits are underway. MDL 3060 is an active multidistrict litigation docket handling these claims. The cases allege the chemicals in hair relaxer products have caused cancer.
  • Women who use hair relaxers often have an increased risk of developing ovarian cancer, uterine cancer and endometrial cancer. Peer-backed studies support this statistic.
  • Product manufacturers allegedly misrepresented the safety of their hair-relaxing products in their marketing. They also targeted women of color and children.

Important hair relaxer lawsuit updates

  • June 2024: 8,170 actions were pending in the hair relaxer MDL. 
  • April 2024: The FDA missed their proposed target date for banning formaldehyde in hair relaxers.

Learn about more hair relaxer lawsuit updates.

Why are people filing hair relaxer cancer lawsuits?

Why are people filing hair relaxer cancer lawsuits?

People are filing hair relaxer cancer lawsuits because they or their loved ones developed cancer after being exposed to dangerous chemicals. Many women use hair relaxers as a part of their normal self-care regimen. However, research and diagnoses have shown a possible link between hair-relaxing chemicals and ovarian cancer, uterine cancer and endometrial cancer.

Hair relaxer lawsuits claim defendants: 

  1. Knew or should have known about the risks of hair-relaxing chemicals
  2. Marketed dangerous products without warning consumers
  3. Misrepresented the products as “safe” and “natural”
  4. Reinforced discriminatory standards of beauty and negative stereotypes about afro-textured hair

These lawsuits began after a 2022 study linked chemical hair relaxers to an increased risk of uterine cancer.  The 2022 study used data from the National Institute of Environmental Health Sciences (NIEHS). The NIEHS is part of the National Institute of Health (NIH). 

Researchers found women who frequently used chemical hair straighteners were more than twice as likely to develop uterine cancer over those who did not.  This study used data from a larger body of research called the Sister Study. The Sister Study followed 50,000 women for 10 years to study cancer and what might cause it.  Earlier research had linked using these products to an increased risk of ovarian cancer. 

People began to file hair relaxer cancer lawsuits shortly after the 2022 NIEHS study. Motley Rice lawyers are currently evaluating potential cases involving these types of cancer:

  • Ovarian cancer
  • Uterine cancer
  • Endometrial cancer

These cancers have been connected with various chemicals present in hair relaxer products.

Is there a hair relaxer class action lawsuit?

A class action and multidistrict litigation (MDL) are currently proceeding in federal court. The MDL consolidates multiple chemical hair straightener lawsuits across the country. The MDL is against hair relaxer manufacturers over the alleged link between the use of hair relaxers and cancer diagnoses. 

As of June 3, 2024, 8,270 actions were pending in the hair relaxer MDL. 

In 2023, Fidelma Fitzpatrick was appointed co-lead counsel for MDL 3060 In re: Hair Relaxer Marketing Sales Practices And Products Liability Litigation in the Northern District of Illinois. Carmen Scott is co-chair of the Leadership Development Committee for the MDL. Tope Leyimu is on the Leadership Development Committee and is co-chair of the L’Oréal Liability Committee.

Contact a hair relaxer lawyer

If you or a loved one was diagnosed with ovarian cancer, uterine cancer or endometrial cancer after using a chemical hair relaxer product, know that you are not alone during this difficult time. For more information or to discuss a potential case, reach out to hair relaxer MDL co-lead Fidelma Fitzpatrick or attorney Tope Leyimu. Call 1-800-768-4026 or email at any time.

Predatory marketing efforts of hair relaxer companies

Predatory marketing efforts of hair relaxer companies

The hair relaxer product market alone is worth hundreds of millions of dollars annually. In 2023, its worth was $690 million  and is expected to grow to $854 million annually by 2028.  Millions of dollars are at stake over one product category. For this reason, manufacturers have also poured millions of dollars into marketing.

Historically, Black and Brown hair textures have been discriminated against and devalued. Cosmetic companies have used branding and slogans to reinforce Eurocentric standards of beauty. But they have not disclosed the full health effects of these products. 

Many defendants named in today’s lawsuits have been marketing their hair-relaxing products since the 1950s, 60s and 70s. As a result, brand loyalty has been passed down for decades. This has led to generations of Black and Brown women using these products long-term. 

Marketing to children misled consumers

In 1990, Godrej (a large multinational company) developed and began marketing Just For Me products. These products targeted children and young women with catchy commercials and colorful packaging. They used depictions of children and language about the “gentle” formula.  Many defendants introduced similar product lines aimed at children.

Misleading language deceived consumers about safety

Hair relaxer manufacturers allegedly used misleading language on hair relaxer packages and advertisements. Below are a few examples. This is not an exhaustive list of allegedly misleading language on hair relaxer products.  

  • Strength of Nature (owned by Godrej) labeled products such as Soft & Beautiful, with language like “Botanicals,” “Natural,” “Gentle” and “Ultra Nourishing.” It also marketed its Beautiful Textures hair relaxer product with the slogan “go from curly to straight and back again without using harsh chemicals!” 
  • Soft Sheen (owned by L’Oréal) labeled its Dark & Lovely brand hair relaxer products as providing a “healthy” gloss and containing “nourishing” shea butter with jojoba and avocado oils. 
  • Namaste (owned by Dabur) marketed its ORS Olive Oil relaxer as a way to “safely elongate tight coils.” 

Plaintiffs allege hair relaxer cancer lawsuit defendants have used misleading labeling and marketing. Whether they called their ingredients “safe,” “natural” or “nourishing,” they all failed to disclose the serious health risks posed to consumers.

Companies and products named in hair relaxer cancer lawsuits

Companies and products named in hair relaxer cancer lawsuits

Several cosmetic companies have been named in the lawsuits for hair relaxers. Some are standalone companies, and others are owned by larger parent companies. Companies involved in hair relaxer claims include: 

  • Avlon
  • Dabur
  • Godrej SON Holdings
  • House of Cheatham
  • JF Labs
  • L’Oréal
  • Luster
  • McBride
  • Namaste Laboratories
  • PDC Brands
  • Revlon Inc.
  • Sally Beauty
  • SoftSheen-Carson
  • Strength of Nature

These companies allegedly manufacture, market and sell dangerous chemical hair relaxer products. More defendants may be added as people continue to file lawsuits.

Harmful hair relaxer products

These companies are responsible for using product ingredients that may increase cancer risk. Many hair relaxer brands and products are involved in these lawsuits. Some examples include: 

  • Affirm®
  • African Pride®
  • Africa’s Best®
  • Cantu
  • Crème of Nature®
  • Dark & Lovely®
  • Design Essentials®
  • Dr. Miracle’s®
  • Dream Kids
  • Hawaiian Silky®
  • Just for Me®
  • Mizani®
  • Motions®    
  • Optimum Care®
  • Organic Root Stimulator™
  • ORS Olive Oil™
  • Pink Conditioning No-Lye Relaxer®
  • Profectiv Mega Growth®
  • Revlon Realistic®
  • Roots of Nature®
  • Silk Elements®
  • Smooth Touch No-Lye Relaxer®
  • Soft & Beautiful®
  • TCB®
  • TCB Naturals®

Some companies, like L’Oréal, are responsible for multiple products. You may not be sure what company is responsible for a product you believe may have caused your cancer. A hair relaxer lawyer may be able to determine the responsible company.

Read about the alleged link between these hair relaxer products and cancer below. 

The alleged link between hair relaxers and cancer

The alleged link between hair relaxers and cancer

A growing body of scientific evidence has allegedly linked chemical hair relaxers to some reproductive cancers. Although many people use these chemical hair relaxer products, Black women are more likely to use them and may be at greater risk.

The NIEHS Sister Study provided data for several other studies. The studies illustrated the link between hair-relaxing chemicals and reproductive cancers. The NIEHS Sister Study was a decade-long study that followed 50,000 women aged 35 – 74.  Some analyses of Sister Study data do not use the entire population of the study.

  • 2021 Sister Study analysis: This analysis looked at data from 40,559 Sister Study participants. It showed that women who used hair-relaxing products four or more times per year were more likely to develop ovarian cancer
  • 2022 Sister Study analysis: This analysis looked at data from 33,497 Sister Study participants. It showed that women who used hair-relaxing products four or more times per year were twice as likely to develop uterine cancer.  

About 60% of the study participants who reported using chemical hair relaxers were Black women. This study confirmed that these risks affect Black women more than others. 

How do hair relaxers cause cancer?

Many of the ingredients in hair relaxers are known endocrine disruptors. Endocrine disruption is linked to reproductive cancers, including ovarian cancer, uterine cancer and endometrial cancer. 

Important terms

  • Endocrine system: A bodily system that creates and releases hormones. It regulates physical growth and development. It also regulates other systems, including the nervous system, reproductive system and metabolism. 
  • Endocrine disruption: Interference with the endocrine system’s natural function. This includes stopping or increasing hormone production and producing hormones when they are not needed. 
  • Endocrine-disrupting chemicals (EDCs): Chemicals and mixtures that hinder the normal activity of the endocrine system. They can block hormone signals by modifying DNA and cell structure. 
  • Reproductive cancers: Cancers affecting the reproductive organs. For women, this includes cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, vulvar cancer and breast cancer.  Endometrial cancer is a type of uterine cancer.

Several EDCs and carcinogens have been found in hair relaxers. Consistent exposure can lead to endocrine disruption and the development of cancer over time. For example, one chemical alleged to cause damage is formaldehyde. 

In 2023, the FDA proposed a ban on formaldehyde and formaldehyde releasing chemicals in hair relaxers. The administration was scheduled to unveil a proposal for the ban in April 2024. No further news about regulatory action had been published by April 30, 2024.  

Hair relaxers and uterine and endometrial cancer

Hair relaxers and uterine and endometrial cancer

In 2022, the Journal of the National Cancer Institute published a study that found an increased risk of uterine cancer in women who use chemical hair relaxers and straighteners.  Endometrial cancer is a type of uterine cancer.  In the study, 94.7% of reported uterine cancer cases were classified as endometrial cancer.

Endometrial cancer begins in the lining of the uterus, called the endometrium. Endometrial cancer often causes symptoms early on. This can, thankfully, lead to early diagnosis and treatment. However, the primary treatment for endometrial cancer is a hysterectomy.  A hysterectomy is a surgical procedure that removes the uterus and cervix.

One of the biggest risk factors for endometrial cancer and uterine cancer is changes in hormones. Hormone changes affect the reproductive organs drastically. 

Endometrial cancer symptoms 

  • Bleeding between periods
  • Pelvic pain
  • Vaginal bleeding after menopause

Contact your healthcare provider for a screening if you experience any of these symptoms.

Hair relaxers and ovarian cancer

Hair relaxers and ovarian cancer

In 2021, a study in the journal Carcinogenesis linked the use of hair relaxers with an increased risk of ovarian cancer.  Ovarian cancers occur in the ovaries, part of the female reproductive system. The study found that women who used hair relaxers four or more times per year were approximately twice as likely to be diagnosed with ovarian cancer.

Ovarian cancer can be hard to diagnose early because symptoms are often downplayed. Many symptoms may present similarly to other common conditions. However, cancer cells can grow quickly. It is important to contact your doctor if you experience ovarian cancer symptoms.

Ovarian cancer symptoms 

  • Abdominal bloating or swelling
  • Back pain
  • Changes in bowel habits, including constipation
  • Fatigue
  • Frequent urination
  • Pelvic discomfort
  • Quickly feeling full when eating
  • Weight loss

A change in hormones is a risk factor for ovarian cancer. 

Hair relaxer lawsuit update timeline

Hair relaxer lawsuit update timeline

06.01.2024

June 2024

Over 8,600 actions are pending in the hair relaxer MDL as of June  2024.  The year started with 8,026 actions pending; that number has increased by more than 570since then. Pending actions refers to the number of individual lawsuits filed within the MDL.

05.01.24

May 2024

Discussions about appointing a Special Master to the lawsuit continued. A Special Master is a neutral person appointed by the court to help manage the complex proceedings. Professor Maura Grossman was appointed Special Master on Electronically Stored Information (ESI) discovery disputes for MDL No. 3060.

04.01.24

April 2024

The FDA missed their April 2024 deadline for the proposed formaldehyde ban on hair straightening products. 

11.01.23

November 2023

The Plaintiffs’ Steering Committee filed a claim to loop Revlon into the MDL. Revlon manufactures, markets and sells hair relaxer products containing harmful chemicals. Revlon was not originally included in the MDL because the parent company, Revlon Inc., filed bankruptcy. The November claim required Revlon to include potential plaintiff compensation in their bankruptcy plan. 

10.01.23

October 2023

The FDA proposed a new ban on the use of formaldehyde and formaldehyde-releasing chemicals in hair relaxers. The proposed ban acknowledged the link between formaldehyde and serious illnesses, including cancer.  The proposal targeted April 2024 for the ban.

08.01.23

August 2023

The U.S. District Court for the Northern District of Illinois Eastern Division approved a Short Form Complaint in the hair relaxer MDL.  A Short Form Complaint is an abbreviated version of a legal complaint filed by an individual plaintiff. It contains the essential information connected to the MDL. This includes claims, allegations and damages. It also references the broad allegations common to all plaintiffs in the MDL. A Short Form Complaint addresses the unique aspects of each plaintiff’s case. However, it is still consistent with the primary issues of the MDL.

05.01.23

May 2023

A new docket entry clarified the process for filing new cases.  New complaints would be filed as a new case in the Northern District of Illinois. Each would receive a unique docket number. The complaint had to include a district’s civil cover sheet connecting the new case with the MDL. The Court’s Clerk’s Office was made responsible for transferring the newly filed case to the MDL.

05.01.23

May 2023

The formal Master Complaint was submitted in federal court. The Master Complaint consolidated the individual complaints and outlined the common allegations. 

03.01.23

March 2023

Motley Rice attorney Fidelma Fitzpatrick was appointed as co-lead counsel for the hair relaxer MDL. A Plaintiff’s Steering Committee (PSC) was nominated. This was because the MDL had several law firms representing the various plaintiffs. The PSC would communicate with the court on behalf of all the plaintiffs. Fitzpatrick and their co-leads would preside over the actions of the PSC.

02.01.23

February 2023

The MDL for hair relaxer marketing, sales practices and products liability litigation was officially approved. It was assigned to the Northern District of Illinois. Plaintiffs were looking for justice and compensation for their injuries caused by hair relaxer products. U.S. District Judge Mary M. Rowland was assigned to the hair relaxer MDL.  

01.01.23

January 2023

The Judicial Panel on Multidistrict Litigation (JPML) held a hearing to determine if the lawsuits will consolidate. The defendants opposed the consolidation. But plaintiffs were optimistic the hearing would have a favorable outcome. The Panel made no formal decision. 

12.01.22

December 2022

The Judicial Panel on Multidistrict Litigation set a hearing date for January 2023. The hearing was for the motion to consolidate the lawsuits into an MDL. During the hearing, the defendants could voice their objections to the MDL.

12.01.22

December 2022

The defendants, including L’Oréal, argued against the consolidated MDL.  The opposition to the MDL would be reviewed by the Judicial Panel on Multidistrict Litigation. 

11.01.22

November 2022

A class action lawsuit was filed against L’Oréal and other hair relaxer companies . This separate case was also filed in the Northern District Court of Illinois. The plaintiffs were seeking restitution for the full purchase price of the products they purchased. The products include hair straighteners and relaxers made by L’Oréal and others. These companies allegedly didn’t disclose that their Serious health risks associated with their products. 

11.01.22

November 2022

After the initial hair relaxer lawsuit, more lawsuits were filed in nineteen districts . Attorneys representing the plaintiffs filed a motion to consolidate the related lawsuits into an MDL. With an MDL, similar cases could be transferred to a single district court. An MDL would streamline discovery, combine resources and ensure consistency in pre-trial rulings. 

10.01.22

October 2022

The National Institutes of Health did a study using data from the Sister Study. They concluded that women who use hair-straightening products have a higher risk for uterine cancer than women who don’t . Using the products more than four times a year doubled their risk of developing uterine cancer.

This study added compelling evidence linking the increase in hormone-related cancers to toxic hair relaxers. This study was released days after the original lawsuits for hair relaxers were filed in Illinois.

10.01.22

October 2022

A 32-year-old woman filed a lawsuit in Illinois against L’Oréal and other companies . Her lawsuit claimed that long-term use of hair-straightening products caused her uterine cancer. The lawsuit alleged that L’Oréal and the other named companies marketed their products as safe and did not warn customers about the increased risk of cancer.

09.01.21

September 2021

The peer-reviewed medical journal Carcinogenesis published an article in September 2021 about a study that links hair products to increased ovarian cancer risk.  The study used data collected by the Sister Study over 10 years. They connected frequent use of hair straightener and relaxer products with an increased risk of ovarian cancer. 

View Full Timeline

Frequently asked questions (FAQs) about hair relaxer cancer lawsuits

Frequently asked questions (FAQs) about hair relaxer cancer lawsuits

When will the hair relaxer lawsuit be settled?

No hair relaxer lawsuit settlements have happened yet. The first hair relaxer lawsuit trials in the hair relaxer MDL will not likely begin until 2025.

With over 8,000 pending actions as of June 3, 2024, many parties are eager for trial dates to be set. Plaintiffs and defendants are currently involved in preparation, discovery and procedural motions. 

Has anyone received a settlement from the hair relaxer lawsuit?

As of June 1, 2024, no one has received a settlement from this hair relaxer lawsuit. Settlement offers generally depend on factors like the strength of the evidence and the risks of going to trial. Both parties must be willing to negotiate. Settlement offers can happen during pre-trial proceedings, close to the trial date or after the trial has begun.

How do you qualify for a hair relaxer lawsuit?

To qualify for a hair relaxer lawsuit, you must be diagnosed with ovarian cancer, uterine cancer or endometrial cancer. If you or someone you love has developed one of these medical issues after long-term use of a hair relaxer, you may have a claim. Contact one of our hair relaxer attorneys to discuss your potential case.

Motley Rice’s experience litigating defective products impacting women

Motley Rice’s experience litigating defective products impacting women

Many people have been impacted by ovarian cancer, uterine cancer or endometrial cancer allegedly caused by using chemical hair relaxers. If you believe you have been similarly impacted, consider discussing your options with an attorney with experience in multidistrict litigation (MDL).

Our attorneys have a depth of experience supporting women and families facing life-altering health problems. We have knowledge that can help you weigh your legal options.

Motley Rice leads litigation brought by thousands of women harmed by defective products. Our law firm has extensive experience litigating product liability lawsuits for women who:

  • Developed ovarian cancer after using talc-based baby powder for feminine hygiene 
  • Suffered breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) allegedly caused by Allergan implants
  • Endured severe complications allegedly caused by birth control devices such as Essure® and Paragard® and complications arising from the use of transvaginal mesh

We’ve also helped mothers who have filed lawsuits for birth defects caused by prescription drugs and necrotizing enterocolitis (NEC) linked to baby formula

We invite you to reach out to our attorneys at any time to discuss a potential case. 

About the Authors

Sources

  1. American Cancer Society. Surgery for Endometrial Cancer.
  2. California Department of Toxic Substances Control. Chemicals in Hair Straightening Products Background Document
  3. Chang CJ, O’Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, et al. Use of straighteners and other hair products and incident uterine cancer. JNCI: Journal of the National Cancer Institute. 2022 Dec 8;114(12):1636–45.
  4. Cleveland Clinic. Endocrine system.
  5. Justia. In Re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation.
  6. Justia. In Re: Hair Relaxer Marketing, Sales, Practices, And Products Liability Litigation No. 1:2023cv00818 - Document 291 (N.D. Ill. 2023).
  7. Justia. Mitchell v. L’Oreal USA, Inc et al
  8. Mayo Clinic. Endometrial cancer.
  9. Mayo Clinic. Ovarian cancer.
  10. Mordor Intelligence LLP. Evolving Landscape of the Hair Relaxer Sector, 2023-2028.
  11. National Institutes of Health. Hair straightening chemicals associated with higher uterine cancer risk.
  12. NPR. FDA move to ban formaldehyde in hair straighteners called too little, too late. 
  13. NPR. The FDA is proposing a ban on hair relaxers with formaldehyde due to cancer concerns.
  14. Reuters. Dabur India's two units dismissed as defendants in hair relaxer lawsuit in US
  15. The Sister Study. What is the Sister Study?
  16. U.S. Department of Health & Human Services. Reproductive Cancers
  17. U.S. Environmental Protection Agency. Overview of Endocrine Disruption.
  18. United States District Court for the Northern District of Illinois. Case Management Order No.7 Adoption of Short Form Complaint.
  19. United States District Court for the Northern District of Illinois. Notification of Docket Entry.
  20. United States Judicial Panel on Multidistrict Litigation. About the Panel
  21. United States Judicial Panel on Multidistrict Litigation. MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending.
  22. White AJ, Sandler DP, Gaston SA, Jackson CL, O’Brien KM. Use of hair products in relation to ovarian cancer risk. Carcinogenesis. 2021 Oct 5;42(9):1189–95.

Your Legal Options

Three simple steps with Motley Rice

Connect with an attorney 1.800.768.4026

1

Submit
Information

Call us or fill out our online form with your case details.

2

Case
Review

Our team meticulously reviews your information to assess your case's potential.

3

Case
Consultation

Discuss next steps with our lawyer for tailored guidance.